View clinical trials related to Femoropopliteal Artery Disease.
Filter by:- Prospective, multi-center, randomized, controlled comparison study - A total of 300 subjects with complex femoropopliteal artery disease will be included according to inclusion and exclusion criteria. Complex lesions include long lesions (>150 mm), calcified lesions (PACSS grade 2-4) and in-stent lesions. - Patients will be randomized in a 1:1 manner into atherectomy plus drug-coated balloon (DCB) or angiography-guided intervention group. • The randomization will be startified by the participating center and in-stent restenosis lesion. • For the DCB treatment, either IN.PACT (Medtronic) or Ranger (Boston Scientific) DCB will be used. • For the atherectomy, HawkOne (Medtronic), Jetstream (Boston scientific), or Rotarex (Straub Medical) will be used. • The primary endpoint is primary patency at 12 months based on Kaplan-Meier survival analysis. • Ankle-brachial index and Image study follow-up (Duplex US, CT angiography, or catheter angiography) will be performed at 1 year. - Patients will be followed clinically for 2 years after the procedure.
- Prospective, randomized, controlled, multi-center study - A total of 220 subjects with long femoropopliteal lesions will be included according to inclusion and exclusion criteria. - Patients will be randomized in a 1:1 manner into long stenting group versus short stenting group. and treated with Zilver PTX for long femoropopliteal lesions - Patients will be followed clinically for 1 year after the procedure. - Image study follow-up (Duplex US or CT angiography) will be performed at 1 year.
- Prospective, single-arm, multi-center registry study - A total of 150 subjects with femoropopliteal artery disease who meet all inclusion and exclusion criteria will be included. - Patients will be followed clinically for 12 months after the procedure. - Duplex ultrasound, CT or catheter-based angiography follow-up according to participating hospital's protocol will be performed at 12 months. - Presence of stent fracture will be evaluated by plain radiography or fluoroscopy at 12 months. - Quality of life by standardized questionnaires (at baseline & at 1 & 12 months)